Joseph N. Contessaمشاهده پروفایل
استاد مدعو
Joseph N. Contessa, MD, PhD is an Adjunct Professor of Therapeutic Radiology and Pharmacology at Yale School of Medicine, where he serves as Director of Yale Medicine's Central Nervous System Radiotherapy Program. His clinical practice focuses on treating patients with brain tumors, head and neck cancers, and tumors at the base of the skull, including rare entities such as low-grade and malignant gliomas, ependymomas, high-grade meningiomas, hemangiopericytomas, paragangliomas, and schwannomas. Dr. Contessa's research spans multiple areas of cancer biology with a particular emphasis on molecular mechanisms of therapeutic resistance and novel approaches to radiosensitization. His work explores the role of N-linked glycosylation in cancer progression and treatment resistance, developing small molecule inhibitors targeting this pathway to overcome resistance to EGFR tyrosine kinase inhibitors. He also investigates targeted therapies for head and neck squamous cell carcinoma, molecular imaging of the epidermal growth factor receptor, and drug discovery through high-throughput screening approaches. Analysis of Dr. Contessa's recent publications reveals a consistent focus on the intersection of radiation oncology and molecular biology, particularly examining how glycosylation pathways influence cancer cell response to radiation and targeted therapies. His work spans basic science investigations into protein folding and quality control mechanisms to clinical applications in lung cancer, brain tumors, and head and neck cancers. A significant portion of his research explores how inhibiting specific glycosylation enzymes can sensitize tumors to radiation therapy. Dr. Contessa actively collaborates with leading researchers at Yale including Veronica Chiang (6 publications), Barbara Burtness (2 publications), Kimberly Johung (2 publications), and Scott Gettinger (2 publications). He serves as a Sub Investigator on the clinical trial 'Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer' (HIC ID 1603017333), which is scheduled for primary completion in June 2026. His laboratory work is closely integrated with clinical care through multiple Yale centers including the Brain Tumor Center, Gamma Knife Center, Head and Neck Cancers Program, and Yale Cancer Center. Dr. Contessa's research bridges basic science discoveries in protein glycosylation with clinical applications in radiation oncology, creating a translational pipeline from bench to bedside for patients with challenging malignancies.
